Ironwood Pharmaceuticals, Inc. - financials
$4.16+0.97%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $113.0M | $106.5M | $47.7M | $122.1M | $85.2M | $41.1M | $90.5M | $91.6M | $94.4M | $74.9M | $117.6M | $113.7M |
| Gross profit | $113.0M | $106.5M | $47.7M | $122.1M | $85.2M | $41.1M | $90.5M | $91.6M | $94.4M | $74.9M | $117.6M | $113.7M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | $79.3M | $72.6M | $6.8M | $75.5M | $45.3M | -$29.1M | $31.5M | $25.6M | $25.0M | $11.0M | $37.6M | $40.0M |
| Net income | $51.3M | $40.8M | -$2.3M | $40.1M | $23.6M | -$37.4M | $2.3M | $3.6M | -$860.0K | -$4.2M | -$1.1M | $15.3M |
| Net margin | 45.4% | 38.3% | −4.8% | 32.8% | 27.7% | −90.9% | 2.5% | 4.0% | −0.9% | −5.6% | −0.9% | 13.5% |
| Diluted EPS | $0.31 | $0.24 | $-0.02 | $0.23 | $0.14 | $-0.23 | $0.01 | $0.02 | $-0.01 | $-0.03 | $-0.01 | $0.09 |
| EBITDA | $79.8M | $73.0M | $7.0M | $78.2M | $45.5M | -$10.1M | $32.0M | $26.2M | $27.6M | $12.0M | $43.7M | $45.2M |
| Operating cash flow | $58.3M | $5.1M | $74.6M | $47.6M | -$15.1M | $20.0M | $15.2M | $9.9M | $33.5M | $45.0M | $35.8M | $32.5M |
| Free cash flow | $58.3M | $5.1M | $74.6M | $47.6M | -$15.1M | $19.9M | $15.2M | $9.9M | $33.4M | $44.9M | -$990.4M | $32.4M |
| Diluted shares | 167.2M | 166.7M | 136.4M | 177.8M | 176.8M | 161.0M | 163.4M | 160.2M | 159.0M | 157.7M | 92.8M | 186.9M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $79.1M | $220.5M | $215.5M | $140.4M | $92.9M | $108.5M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $385.0M | $584.9M | $584.7M | $584.5M | $584.3M | $584.2M |
| Total assets | $285.1M | $434.6M | $396.9M | $396.1M | $342.9M | $327.2M |
| Total liabilities | $447.0M | $651.7M | $658.7M | $660.2M | $651.1M | $661.3M |
| Shareholders' equity | -$161.8M | -$217.1M | -$261.8M | -$264.2M | -$308.2M | -$334.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology